Home › Compare › EXROF vs JNJ

EXROF vs JNJ: Dividend Comparison 2026

EXROF yields 200000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EXROF wins by $4.911780474428384e+29M in total portfolio value
10 years
EXROF
EXROF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full EXROF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EXROF vs JNJ

📍 EXROF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEXROFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EXROF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EXROF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EXROF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, EXROF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EXROF + JNJ for your $10,000?

EXROF: 50%JNJ: 50%
100% JNJ50/50100% EXROF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EXROF
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
-21.9
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EXROF buys
0
JNJ buys
0
No recent congressional trades found for EXROF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEXROFJNJ
Forward yield200000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$4.911780474428384e+29M$20.0K ✓
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$4.911464459982279e+29M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: EXROF vs JNJ ($10,000, DRIP)

YearEXROF PortfolioEXROF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$20,010,700$20,000,000.00$10,676$355.77+$20.00M → EXROF
2$37,424,589,019$37,403,177,570.09$11,407$389.39+$37424.58M → EXROF
3$65,416,215,188,220$65,376,170,877,969.18$12,198$426.53+$65416215.18M → EXROF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$13,056$467.62+$106868230495.00M → EXROF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$13,987$513.12+$163172871735896.88M → EXROF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$14,998$563.56+$232854599801468864.00M → EXROF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$16,098$619.52+$310570858137017057280.00M → EXROF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$17,295$681.69+$3.871481543016132e+23M → EXROF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$18,599$750.82+$4.510617497632811e+26M → EXROF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$20,022$827.78+$4.911780474428384e+29M → EXROF

EXROF vs JNJ: Complete Analysis 2026

EXROF — Stock

Exro Technologies Inc. focuses on developing and commercializing patented coil driver technology and proprietary system architecture for power electronics. The company's technology expands the capabilities of electric motors, generators, and batteries. It also develops the battery control system that provides energy storage system solutions for first and second life batteries. Exro Technologies Inc. was incorporated in 2014 and is headquartered in Calgary, Canada.

Full EXROF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EXROF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EXROF vs SCHDEXROF vs JEPIEXROF vs OEXROF vs KOEXROF vs MAINEXROF vs ABBVEXROF vs MRKEXROF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.